US.BIIB · Biogen

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 4.578571553057354,
        "turnoverUsdM": 236.95030850300003,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.BIIB",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 187.1272,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 9.2,
      "take_profit_price": 218.3137,
      "target_multiplier": 1.6,
      "technical_strength": 1.22,
      "take_profit_percent": 6
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.2,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 9.157143106114708,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 55.1,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 43.1,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 12
  },
  "market": {
    "ma20": 204.766,
    "ma50": 198.8126,
    "close": 205.99,
    "prevClose": 208.92,
    "avgVolume20": 1627040,
    "volumeRatio": 0.71,
    "changePercent": -1.4
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 12,
    "details": {
      "ret_5d": 0.03434607252553712,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 12,
      "vcp_bonus": 0,
      "vol_ratio": 0.7100726863068875,
      "ret_points": 8,
      "vol_points": 0,
      "range_ratio": 1.5120317074246397,
      "volat_points": 4,
      "day_range_pct": 0.06014854798055491,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 55.1,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 56,
        "contribution": 2.8
      },
      {
        "raw": 6.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 34,
        "contribution": 6.8
      },
      {
        "raw": 5.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 34.67,
        "contribution": 5.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 5.7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 57,
        "contribution": 5.7
      },
      {
        "raw": 18.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 62,
        "contribution": 18.6
      },
      {
        "raw": 2,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 20,
        "contribution": 2
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 43.1,
    "details": [
      "基本面分析總分: 2.8/5分",
      "資金流分析總分: 6.8/20分",
      "市場環境分析總分: 5.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 5.7/10分",
      "技術信號分析總分: 18.6/30分",
      "情緒分析: 2/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.8,
      "資金流": 6.8,
      "市場環境": 5.2,
      "情緒分析": 2,
      "技術信號": 18.6,
      "風險管理": 5.7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.4,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 236.95030850300003,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 0.8,
          "vwapPoints": 2.4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BIIB",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 718.34550435,
                "ma50": 719.0052026400002,
                "name": "QQQ",
                "close": 695.33002,
                "points": 0.4
              },
              "spy": {
                "ma20": 745.021005,
                "ma50": 744.3804017000001,
                "name": "SPY",
                "close": 743.28998,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 4.578571553057354,
          "atrPoints": 2,
          "cciPoints": 2.4,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 0,
              "sentimentScoreRaw": 0
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140909943,
                "url": "https://finnhub.io/api/news?id=b23004b2e6eee8b89d9c2ca4bbc24aea8227d09c1937a787636ff354968adf86",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen’s 14.4% return over the past six months has outpaced the S&P 500 by 6.2%, and its stock price has climbed to $192.84 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1784128637,
                "headline": "3 Reasons to Avoid BIIB and 1 Stock to Buy Instead"
              },
              {
                "id": 140905338,
                "url": "https://finnhub.io/api/news?id=8e3e5f4d6f541304dd96b8ca7c08abee57966960c4ef5141f7dcf81cdf146ba9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) is back in focus after fresh Alzheimer’s data, including new real world results for LEQEMBI and Phase 2 findings for tau targeting candidate diranersen, gave investors more information on the company’s neurology pipeline. See our latest analysis for Biogen. Despite the positive Alzheimer’s headlines, Biogen’s 1 day share price return was down 8.17% and the 7 day share price return was down 6.68%. However, the year to date share price return of 7.95% and 1 year total shareholder...",
                "category": "company",
                "datetime": 1784081483,
                "headline": "Biogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intact"
              },
              {
                "id": 140903730,
                "url": "https://finnhub.io/api/news?id=f64b8b857c66457bc04df5fec443525de7d9d706504395c3e55696b5300cd6df",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "2026-07-14. The following slide deck was published by Biogen Inc.",
                "category": "company",
                "datetime": 1784055667,
                "headline": "Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 - Slideshow"
              },
              {
                "id": 140901727,
                "url": "https://finnhub.io/api/news?id=83d154d750f01f5513fbb6bfce3a640282e0c0a9d877d79ca5f38b08d275222c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen’s mid-stage trial of diranersen did not meet its main goal of showing a clear relationship between higher doses and better results.",
                "category": "company",
                "datetime": 1784054309,
                "headline": "BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study"
              },
              {
                "id": 140902562,
                "url": "https://finnhub.io/api/news?id=a820614b62bcd511dc1e0ec626c3a18e6709881c065fed16f0a31886d326a49b",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen Inc. (BIIB) Alzheimer's Association International Conference (AAIC Meeting) 2026 July 12, 2026 11:15 AM EDTCompany ParticipantsTim Power - Head of...",
                "category": "company",
                "datetime": 1784050148,
                "headline": "Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript"
              },
              {
                "id": 140898432,
                "url": "https://finnhub.io/api/news?id=2850f575f0c0ac756ca144ad8124dc0026e814bffab100311cd4dabf6dd56b3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Eisai and Biogen recently received FDA approval for LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector initiation dose that allows adults with early Alzheimer’s disease to start and continue treatment at home instead of relying solely on intravenous infusions in clinics. This at-home option, supported by data showing exposure equivalent to IV dosing and high ease-of-use ratings from patients and care partners, could meaningfully change how Alzheimer’s therapies are delivered and accessed...",
                "category": "company",
                "datetime": 1784038479,
                "headline": "How Investors Are Reacting To Biogen (BIIB) At-Home LEQEMBI Autoinjector Approval"
              },
              {
                "id": 140897185,
                "url": "https://finnhub.io/api/news?id=5125b91b018246b3e62db8e2c2ea2b077856ecc0b47816e0538f5927102d1e96",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. (NASDAQ:BIIB) traded higher after releasing encouraging Phase 2 data for its experimental Alzheimer’s treatment, diranersen, with results showing meaningful reductions in tau pathology alongside improvements across several measures of cognitive decline.",
                "category": "company",
                "datetime": 1784036917,
                "headline": "Biogen Shares Rise After Positive Phase 2 Alzheimer’s Trial Results (BIIB)"
              },
              {
                "id": 140890177,
                "url": "https://finnhub.io/api/news?id=8e5d11b1bb207cfa389f939c829219b507d74d7f791eeac7746b1e3d00e9430e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The decision marks a major shift in how patients can begin therapy for early Alzheimer’s disease.",
                "category": "company",
                "datetime": 1783970517,
                "headline": "BIIB Stock Jumps 5% — Analysts Raise Price Targets After FDA Clears Alzheimer’s Treatment For At-Home Use"
              }
            ],
            "raw_source": [
              {
                "id": 140949639,
                "url": "https://finnhub.io/api/news?id=e66915f61a8325ddeb71fb49741e5b27430464cdf2d2993d7cfdc35c9c26a86d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1366552805/image_1366552805.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Stoke Therapeutics outlook: Phase 3 Dravet program catalysts, strong cash runway, and upside from partnerships. Click for more on STOK stock.",
                "category": "company",
                "datetime": 1784427316,
                "headline": "Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch"
              },
              {
                "id": 140922873,
                "url": "https://finnhub.io/api/news?id=afe3ab276daa701b92f1c15194aafe1b2b9513fc46ee50671f3a9b8925c2a053",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25 years of life sciences leadership experience, including serving as CFO of Verona Pharma, where he helped guide […] The post Slate Medicines Appoints Mark W. Hahn to Board of Directors appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1784218733,
                "headline": "Slate Medicines Appoints Mark W. Hahn to Board of Directors"
              },
              {
                "id": 140919017,
                "url": "https://finnhub.io/api/news?id=0574ac5a1c3475f752dcc68f3aeb53389a6a1e7115c90f8fba19919eab9e016a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with neurodegenerative diseases, today announced the launch of a virtual ataxia care program. This program can help to provide timely access to specialized care for adults living with ataxias — a group of neurological conditions characterized by progressive loss of coordination, balance, and motor function. Synapticure partnered with Biogen Inc. (Nasdaq: BIIB) to support dise",
                "category": "company",
                "datetime": 1784202420,
                "headline": "Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide"
              },
              {
                "id": 140909943,
                "url": "https://finnhub.io/api/news?id=b23004b2e6eee8b89d9c2ca4bbc24aea8227d09c1937a787636ff354968adf86",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen’s 14.4% return over the past six months has outpaced the S&P 500 by 6.2%, and its stock price has climbed to $192.84 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.",
                "category": "company",
                "datetime": 1784128637,
                "headline": "3 Reasons to Avoid BIIB and 1 Stock to Buy Instead"
              },
              {
                "id": 140909556,
                "url": "https://finnhub.io/api/news?id=078bec1491fb0d2386bee78b68cb24d0e112102bf4d9c5e65ba67d4356afdbbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.",
                "category": "company",
                "datetime": 1784127060,
                "headline": "Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data"
              },
              {
                "id": 140908577,
                "url": "https://finnhub.io/api/news?id=ef10b299ed3f00e94085a86fcc122614315b2cac68067065e1ece1e64bce7109",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A. Viehbacher, President and Chief Executive Officer. In this role, Mr. Parini will have responsibility for oversight of Biogen’s global legal and compliance functions. “Michael brings to Biogen a rare combination of deep legal an",
                "category": "company",
                "datetime": 1784117700,
                "headline": "Biogen Appoints Michael J. Parini as Chief Legal Officer"
              },
              {
                "id": 140907578,
                "url": "https://finnhub.io/api/news?id=c9a17f44db5a334c035e6ea894b335b18b541a949a6999656ebfaf5a0e0d5595",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Data released by Biogen at AAIC26 appears to have spooked investors, with an 8.17% drop in share price.",
                "category": "company",
                "datetime": 1784114717,
                "headline": "AAIC26: Biogen stock drops after unveiling tau-targeting ASO data"
              },
              {
                "id": 140907005,
                "url": "https://finnhub.io/api/news?id=4c34e63184f76bf7a57fc384113207254a1cea90cf20bffe8628c9e23db58712",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1046071676/image_1046071676.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "As evidence piled up that amyloid is not going to be the answer in Alzheimer's, tau has been on the upswing. Now we have another test: Diranersen, an antisense oligo from Biogen and Ionis.",
                "category": "company",
                "datetime": 1784096400,
                "headline": "Tau In The Clinic, Again"
              },
              {
                "id": 140905338,
                "url": "https://finnhub.io/api/news?id=8e3e5f4d6f541304dd96b8ca7c08abee57966960c4ef5141f7dcf81cdf146ba9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) is back in focus after fresh Alzheimer’s data, including new real world results for LEQEMBI and Phase 2 findings for tau targeting candidate diranersen, gave investors more information on the company’s neurology pipeline. See our latest analysis for Biogen. Despite the positive Alzheimer’s headlines, Biogen’s 1 day share price return was down 8.17% and the 7 day share price return was down 6.68%. However, the year to date share price return of 7.95% and 1 year total shareholder...",
                "category": "company",
                "datetime": 1784081483,
                "headline": "Biogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intact"
              },
              {
                "id": 140901109,
                "url": "https://finnhub.io/api/news?id=deff9c90bb7e909239d4818d05eb00911aa88c16bd160a2315a273ea8e21cb70",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1784055900,
                "headline": "Discover which S&P500 stocks are making waves on Tuesday."
              },
              {
                "id": 140897980,
                "url": "https://finnhub.io/api/news?id=f61a94464a694de7ff39e9d9539738b692e155b597a056dcbf1cdda87ce22960",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "FEATURE  Stocks were rising Tuesday as investors responded to cooler- than-expected U.S. inflation data for June, a slew of bank earnings reports, and a profit warning from IBM that sent the stock down sharply.",
                "category": "company",
                "datetime": 1784055840,
                "headline": "IBM, Goldman Sachs, SK Hynix, Micron, AMD, Apple, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140901726,
                "url": "https://finnhub.io/api/news?id=843f0eefaa2e7301af9fcdf72ad9e106a5d1948594c88e2c6d424cf6fb246178",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (NASDAQ:BIIB) said data from its Phase 2 CELIA study of diranersen in early Alzheimer’s disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary endpoint of demonstrating a predefined dose-response pattern. The company presented the update dur",
                "category": "company",
                "datetime": 1784055729,
                "headline": "Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss"
              },
              {
                "id": 140903730,
                "url": "https://finnhub.io/api/news?id=f64b8b857c66457bc04df5fec443525de7d9d706504395c3e55696b5300cd6df",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "2026-07-14. The following slide deck was published by Biogen Inc.",
                "category": "company",
                "datetime": 1784055667,
                "headline": "Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 - Slideshow"
              },
              {
                "id": 140901727,
                "url": "https://finnhub.io/api/news?id=83d154d750f01f5513fbb6bfce3a640282e0c0a9d877d79ca5f38b08d275222c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen’s mid-stage trial of diranersen did not meet its main goal of showing a clear relationship between higher doses and better results.",
                "category": "company",
                "datetime": 1784054309,
                "headline": "BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study"
              },
              {
                "id": 140901438,
                "url": "https://finnhub.io/api/news?id=9fd95fbb80f47cce96cfbcae493bee66c1a8f0e6fab86029428940d7057e1de6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The presentation on  Biogen’s  experimental Alzheimer’s treatment at a medical meeting Tuesday was supposed to boost confidence in its drug’s prospects.  Instead, Biogen stock is down 6%, to $197.  Tuesday’s presentation on the drug diranersen, at London’s Alzheimer’s Association International Conference, left attendees confused about what to conclude from Biogen’s Phase 2 study known as CELIA.",
                "category": "company",
                "datetime": 1784052540,
                "headline": "Biogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problem"
              },
              {
                "id": 140900024,
                "url": "https://finnhub.io/api/news?id=dc7da346181b0f2ceb39f461126fe7731235d0cb02fbf8edee8bfb962e0c285e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The mid-stage study missed its primary goal, and the drug's lowest dose outperformed higher doses in ways the company cannot yet explain",
                "category": "company",
                "datetime": 1784050581,
                "headline": "Biogen stock falls 8% on Alzheimer's drug diranersen trial data"
              },
              {
                "id": 140902562,
                "url": "https://finnhub.io/api/news?id=a820614b62bcd511dc1e0ec626c3a18e6709881c065fed16f0a31886d326a49b",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen Inc. (BIIB) Alzheimer's Association International Conference (AAIC Meeting) 2026 July 12, 2026 11:15 AM EDTCompany ParticipantsTim Power - Head of...",
                "category": "company",
                "datetime": 1784050148,
                "headline": "Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript"
              },
              {
                "id": 140899157,
                "url": "https://finnhub.io/api/news?id=f91db0d4afe78455d4f9df00a17b8cf4e2e599781c52c715e4b5f564b7ba2873",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below.",
                "category": "company",
                "datetime": 1784048700,
                "headline": "These S&P500 stocks have an unusual volume in today's session"
              },
              {
                "id": 140898964,
                "url": "https://finnhub.io/api/news?id=76a3fb9d03f8bf894bf401ec3d9d7e7a7980e4769b9be8dd004e0986d25fa30d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.",
                "category": "company",
                "datetime": 1784046901,
                "headline": "These S&P500 stocks are moving in today's session"
              },
              {
                "id": 140899731,
                "url": "https://finnhub.io/api/news?id=ab9efa283f15df1648247f3f9e34e0ef7c686344770d8bd769c997f910e901a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BIIB secures FDA approval for Leqembi Iqlik, letting early Alzheimer's patients start with a weekly at-home autoinjector instead of biweekly IV infusions.",
                "category": "company",
                "datetime": 1784045640,
                "headline": "Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi"
              },
              {
                "id": 140898429,
                "url": "https://finnhub.io/api/news?id=153a92e7c1d3306b0bf3dac06054d4aef60c4ba31ec9ccace2d09042ec9629b7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Investing.com -- Biogen Inc. (NASDAQ:BIIB) shares fell nearly 9% following the Phase 2 CELIA readout of its highly anticipated Alzheimer’s therapy, diranersen. While the drug achieved a major scientific milestone by robustly clearing tau pathology, an unexpected inverse dose response—where the lowest dose performed the best—left Wall Street analysts confused and triggered a sell-off. Diranersen missed its primary endpoint: proving a dose-dependent response on the CDR-SB, a key measure of cogniti",
                "category": "company",
                "datetime": 1784044872,
                "headline": "Biogen tumbles 8.7% as breakthrough Alzheimer’s data is clouded by dosing paradox"
              },
              {
                "id": 140898430,
                "url": "https://finnhub.io/api/news?id=a9e06211335096289748ba9a37a41671ec2c348e9241124092af0e8e0ffebc5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.",
                "category": "company",
                "datetime": 1784042341,
                "headline": "Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers'"
              },
              {
                "id": 140898431,
                "url": "https://finnhub.io/api/news?id=aa2dcbdc57f26604d5c33242d8e2a691b612fb54dcc749217defc31eaa1192bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial SettingTOKYO and CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study show that nearly 83% of early Alzheimer’s disease (AD) patients enrolled in the study remained stable (75.9%) or",
                "category": "company",
                "datetime": 1784042280,
                "headline": "LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment"
              },
              {
                "id": 140897584,
                "url": "https://finnhub.io/api/news?id=e89def7c0ac59e2c2278d3bdc4ee12a87bb928101e8b6a227c378a65a8572717",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends.",
                "category": "company",
                "datetime": 1784039701,
                "headline": "What's going on in today's session: S&P500 gap up and gap down stocks"
              },
              {
                "id": 140898432,
                "url": "https://finnhub.io/api/news?id=2850f575f0c0ac756ca144ad8124dc0026e814bffab100311cd4dabf6dd56b3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Eisai and Biogen recently received FDA approval for LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector initiation dose that allows adults with early Alzheimer’s disease to start and continue treatment at home instead of relying solely on intravenous infusions in clinics. This at-home option, supported by data showing exposure equivalent to IV dosing and high ease-of-use ratings from patients and care partners, could meaningfully change how Alzheimer’s therapies are delivered and accessed...",
                "category": "company",
                "datetime": 1784038479,
                "headline": "How Investors Are Reacting To Biogen (BIIB) At-Home LEQEMBI Autoinjector Approval"
              },
              {
                "id": 140898433,
                "url": "https://finnhub.io/api/news?id=335e15dbc6b4c650190727b5035fcb51690cdbf9586238b463e0e01264c1a27d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.",
                "category": "company",
                "datetime": 1784037840,
                "headline": "Ionis Begins Dosing in Phase I/II Dravet Syndrome Study"
              },
              {
                "id": 140897184,
                "url": "https://finnhub.io/api/news?id=12dae6227d028324d7acc54f0812561d6047c17fa2eee53843c805ce883612df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.",
                "category": "company",
                "datetime": 1784037012,
                "headline": "Can Biogen Score Another Win In Alzheimer's Disease?"
              },
              {
                "id": 140897185,
                "url": "https://finnhub.io/api/news?id=5125b91b018246b3e62db8e2c2ea2b077856ecc0b47816e0538f5927102d1e96",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. (NASDAQ:BIIB) traded higher after releasing encouraging Phase 2 data for its experimental Alzheimer’s treatment, diranersen, with results showing meaningful reductions in tau pathology alongside improvements across several measures of cognitive decline.",
                "category": "company",
                "datetime": 1784036917,
                "headline": "Biogen Shares Rise After Positive Phase 2 Alzheimer’s Trial Results (BIIB)"
              },
              {
                "id": 140897186,
                "url": "https://finnhub.io/api/news?id=c60c35a9692c2c3683e6fb2211ac66f07db16a4a666a1524b83019e046512e28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of clinical decline on the cognitive endpoints—42% on ADAS-Cog13 and 50% on MMSE—alongside a 26% slowing on CDR-SBBiomarker response: Diranersen is the first tau-directed therapy to demonstrate robust reductions in both CSF total tau, with mean reductions of 50–65%, and brain t",
                "category": "company",
                "datetime": 1784034900,
                "headline": "Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease"
              },
              {
                "id": 140900720,
                "url": "https://finnhub.io/api/news?id=982d691f7bdf984c9054330e7605835e8313c537db0cb3b10f02c37d43a0b613",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/14/Biogen-World-Headquarters-At-225-Binney-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen stock drops 9% as Phase 2 diranersen data raises analyst questions, despite Phase 3 plans and a new weekly LEQEMBI FDA approval.",
                "category": "company",
                "datetime": 1784029742,
                "headline": "Why Is Biogen Stock Falling Tuesday?"
              },
              {
                "id": 140900721,
                "url": "https://finnhub.io/api/news?id=93fd7a9af496e79891ad78bb9310c38b4aa0dc82811f9bf6f330a567d276d683",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study show that nearly 83% of early Alzheimer’s disease (AD) patients",
                "category": "company",
                "datetime": 1784028514,
                "headline": "Eisai And Biogen Present Real‑World LEADER Study Data At AAIC Showing Nearly 83% Of Early Alzheimer’s Patients Remained Stable Or Improved On LEQEMBI Therapy Over ~17 Months, With Consistent Results Across Diverse Groups."
              },
              {
                "id": 140896087,
                "url": "https://finnhub.io/api/news?id=befb0ac9f26bb3b83c29adbffc620cf85b5952f9878e208e6f66245506b91a64",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.",
                "category": "company",
                "datetime": 1784026991,
                "headline": "1 Mid-Cap Stock to Target This Week and 2 We Find Risky"
              },
              {
                "id": 140897843,
                "url": "https://finnhub.io/api/news?id=520d796eabd894cbc585550389a8e02addcd2d87cb2f7df5a7f677886dfd3db0",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer’s",
                "category": "company",
                "datetime": 1784020668,
                "headline": "Biogen's Diranersen Demonstrates Efficacy Throughout All Doses In Phase 2 CELIA Trial Of Alzheimer’s Disease; Consistent Efficacy Seen Across Multiple Prespecified Secondary Endpoints Including Clinical Dementia Rating Sum Of Boxes"
              },
              {
                "id": 140891446,
                "url": "https://finnhub.io/api/news?id=f9c0d5351e0b9b5a757351be14bd40c1d9a9fd87679c441cf74bd62fa0039c50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose planned for late August 2026 TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once-weekly lecanemab-irmb subc",
                "category": "company",
                "datetime": 1783978680,
                "headline": "FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease"
              },
              {
                "id": 140890177,
                "url": "https://finnhub.io/api/news?id=8e5d11b1bb207cfa389f939c829219b507d74d7f791eeac7746b1e3d00e9430e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The decision marks a major shift in how patients can begin therapy for early Alzheimer’s disease.",
                "category": "company",
                "datetime": 1783970517,
                "headline": "BIIB Stock Jumps 5% — Analysts Raise Price Targets After FDA Clears Alzheimer’s Treatment For At-Home Use"
              },
              {
                "id": 140900723,
                "url": "https://finnhub.io/api/news?id=ca9d4d6a80beba733a20279a421f2f5e1a11de4e8ca3e19c8c9b9fc25d4cbfc2",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "TOKYO and CAMBRIDGE, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License",
                "category": "company",
                "datetime": 1783964529,
                "headline": "Eisai Co And Biogen Receive FDA's Approval For A Supplemental Biologics License Application For A Once-Weekly Lecanemab-Irmb Subcutaneous Injection As An Initiation Dose For The Treatment Of Early Alzheimer’s Disease; U.S. Launch Of LEQEMBI IQLIK As An Initiation Dose Planned For Late August 2026"
              },
              {
                "id": 140888368,
                "url": "https://finnhub.io/api/news?id=8460d2a47f8d87174a291290655a443a37f1c416d86d29c3f103d568cf8f36e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "A global chip sector's retreat dragged the Nasdaq lower this morning, as oil surged today, July 13, 2026.",
                "category": "company",
                "datetime": 1783961298,
                "headline": "Stock Market Today, July 13: SK Hynix Tumbles 15% in South Korea, Leading Semiconductor Drop at Midday"
              },
              {
                "id": 140888306,
                "url": "https://finnhub.io/api/news?id=57bedb73d41617dfb4ded24cd68d45f832ba1061ba4289dba14cb6cdb4b41c61",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Energy names help cushion the Dow as oil jumps on U.S.–Iran tensions and investors brace for key earnings and inflation data, today, July 13, 2026.",
                "category": "company",
                "datetime": 1783960490,
                "headline": "Stock Market Today, July 13: Energy Stocks Cushion Dow as Tech Slides on Geopolitical Tensions"
              },
              {
                "id": 140900724,
                "url": "https://finnhub.io/api/news?id=b9875427c33851f5f86319e415a4699bcd47afc86e558a1f0abdcc0860d23a4f",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment",
                "category": "company",
                "datetime": 1783952611,
                "headline": "FDA Grants Approval For At-Home Starting Dose For Alzheimer's Treatment Leqembi"
              },
              {
                "id": 140885931,
                "url": "https://finnhub.io/api/news?id=d9bd3e5a447e59b21f811bc30301952ad049da7bb5153d18da437fe995ccd6e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "American Express, Biogen upgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1783950101,
                "headline": "American Express, Biogen upgraded: Wall Street's top analyst calls"
              },
              {
                "id": 140886004,
                "url": "https://finnhub.io/api/news?id=fa383cbd374bde41988e115d4cbc03b8495b70bbef286e24aa0b170187d47707",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Investing.com -- Truist Securities upgraded Biogen to Buy from Hold and raised its price target to $235 from $190, citing growing confidence in the company’s Alzheimer’s and immunology pipeline ahead of several major clinical data readouts over the next two years.",
                "category": "company",
                "datetime": 1783945865,
                "headline": "Truist upgrades Biogen to Buy on Alzheimer’s, pipeline optimism ahead of key data"
              },
              {
                "id": 140887976,
                "url": "https://finnhub.io/api/news?id=4c3d77f1a79e40782699f426e87e3204d2534ab1d16dfaf918d148c20850134c",
                "image": "https://image.cnbcfm.com/api/v1/image/108199413-17580401582025-04-02t111950z_1380151334_rc2ipdal2hwb_rtrmadp_0_china-autos-nio.jpeg?v=1758040200&w=1920&h=1080",
                "source": "CNBC",
                "related": "BIIB",
                "summary": "These are the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1783945286,
                "headline": "Stocks making the biggest moves midday: Nio, Braiin, AppLovin, SpaceX, SK Hynix & more"
              },
              {
                "id": 140886039,
                "url": "https://finnhub.io/api/news?id=deaa3f473f31c034a7009e39b7925d988ebd1dc02951a5d390f868977365a056",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen stock receives a bullish upgrade based on expectations the market will cheer the company’s detailed data on its experimental Alzheimer’s drug.",
                "category": "company",
                "datetime": 1783944900,
                "headline": "Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details"
              },
              {
                "id": 140884998,
                "url": "https://finnhub.io/api/news?id=f1dc7be06c985cbaad59d7b32ea80790ba8f2868c8933acd882df5884c2cce60",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Pre-Market Stock Futures: Futures are trading lower as we get ready for the start of second-quarter earnings this week, after a solid winning week on Wall Street. Renewed strikes against Iran and a chip sell-off are weighing on shares on Monday. All of the major indices closed higher on Friday, except the small-cap Russell 2000, ... Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More",
                "category": "company",
                "datetime": 1783943713,
                "headline": "Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More"
              },
              {
                "id": 140886476,
                "url": "https://finnhub.io/api/news?id=43dc3f2fbf49498f6c2f58a8aa218fa43ebfdadaa4aa691f465c7bacff007dfd",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/13/Biogen-World-Headquarters-At-225-Binney-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Top Wall Street analysts changed their outlook on top names. Upgrade on NIO, COF, KEYS, BIIB, and AXP, see other ratings and consider buying BIIB.",
                "category": "company",
                "datetime": 1783926444,
                "headline": "This Biogen Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday"
              },
              {
                "id": 140887904,
                "url": "https://finnhub.io/api/news?id=db3a5579652ad3e0b4c058ea23ea680be5a0acb9b2db978431301472f4f8a05e",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Truist Securities  analyst Srikripa Devarakonda   upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and raises the price target from $190 to $235.",
                "category": "company",
                "datetime": 1783923365,
                "headline": "Truist Securities Upgrades Biogen to Buy, Raises Price Target to $235"
              },
              {
                "id": 140883870,
                "url": "https://finnhub.io/api/news?id=7d9c0210dd5016813383530a69f6e183d6b937f6e47ce51e35e4ac29e44a8524",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London.",
                "category": "company",
                "datetime": 1783922400,
                "headline": "Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?"
              },
              {
                "id": 140877927,
                "url": "https://finnhub.io/api/news?id=17b571e95a42f5259063ff686b5579fcb312c6b1706c1cbc9b26df7dd9423210",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partnersTOKYO and CAMBRIDGE, Mass., July 12, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer’s Association International Conference® (AAIC®) 2026 in London support that the LEQEMBI® (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers e",
                "category": "company",
                "datetime": 1783869480,
                "headline": "LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026"
              },
              {
                "id": 140865207,
                "url": "https://finnhub.io/api/news?id=9604213b42f7aaf1d99a512e44898a5460795c6fe001db0655b9872a4f7dc48b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with more catalysts still ahead.",
                "category": "company",
                "datetime": 1783712254,
                "headline": "Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up"
              },
              {
                "id": 140860831,
                "url": "https://finnhub.io/api/news?id=70bace5e39146e0e64ac0773b15c6a491cc88cb329eb3be14cd2305070834fcd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.",
                "category": "company",
                "datetime": 1783683335,
                "headline": "The Long Climb Back For Ionis Stock"
              },
              {
                "id": 140860719,
                "url": "https://finnhub.io/api/news?id=6ba326b18f13f774e3be2178a746990fab5ebabf0720aaaace213b57a39dd47e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 11.5% over the past six months, topping the S&P 500 by 4.3 percentage points.",
                "category": "company",
                "datetime": 1783683320,
                "headline": "1 Healthcare Stock with Solid Fundamentals and 2 We Brush Off"
              },
              {
                "id": 140852407,
                "url": "https://finnhub.io/api/news?id=93c73432a1e7673d15bfa810df331e53f5a7211080e7837c9bb9d89d1c99a5a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease that can affect multiple organ systems, with disease severity and clinical manifestations varying considerably among patients. Despite significant advances in understanding its pathophysiology, SLE remains incurable, and current treatment strategies primarily focus on controlling disease activity, achieving remission or low disease activity, preventing irreversible organ damage, minimizing flares, and improving patients'",
                "category": "company",
                "datetime": 1783607460,
                "headline": "Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight"
              },
              {
                "id": 140854879,
                "url": "https://finnhub.io/api/news?id=ce65ce2b089fd2cf93623cc7ccd97daa63d0593a026508e2b80549b26b9c0fb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen is poised to announce its second-quarter results later this month, and analysts predict a double-digit drop in the company’s bottom-line figure.",
                "category": "company",
                "datetime": 1783600099,
                "headline": "Biogen's Q2 2026 Earnings: What to Expect"
              },
              {
                "id": 140850088,
                "url": "https://finnhub.io/api/news?id=e847fedf43124783edcb753cd3d81470a44d61c96f4b63d34a1e67601b823d3c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "On July 8, 2026, Moderna, Inc. appointed veteran financial executive Michael McDonnell, former Biogen CFO, to its Board of Directors and Audit Committee, while a federal advisory panel previously backed approval of the company’s first-of-its-kind mRNA influenza vaccine. Together with new programs in autoimmune disease, ovarian cancer and an AI-enabled research platform, these developments highlight Moderna’s push to broaden its mRNA franchise beyond COVID-19 and seasonal respiratory...",
                "category": "company",
                "datetime": 1783591935,
                "headline": "Will New Board Appointment And mRNA Flu Progress Change Moderna's (MRNA) Pipeline Diversification Narrative?"
              },
              {
                "id": 140841649,
                "url": "https://finnhub.io/api/news?id=46cf1067762772bdaff0bf3cd43eb85b6816d116b9c6119f06b2aaa77d698dba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th",
                "category": "company",
                "datetime": 1783523510,
                "headline": "Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says"
              },
              {
                "id": 140853032,
                "url": "https://finnhub.io/api/news?id=4bb3e9d835d280ecf692c6bf349520f28767a8c3e8cc28198384b66c3201336e",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Morgan Stanley  analyst Matthew Harrison   maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $224 to $222.",
                "category": "company",
                "datetime": 1783513509,
                "headline": "Morgan Stanley Maintains Equal-Weight on Biogen, Lowers Price Target to $222"
              },
              {
                "id": 140842286,
                "url": "https://finnhub.io/api/news?id=7f70607135913a747248cddc872c58baa0448ad7a4f6f85e64e0d2058870d996",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "A July filing shows that Representative Maria Elvira Salazar reported a purchase in Brookfield Renewable (NYSE:BEP), valued between $50,008 and $225,000. The transaction date is listed as June 4, 2026, with the report",
                "category": "company",
                "datetime": 1783508412,
                "headline": "Congressional Trading Report: Rep. Maria Elvira Salazar Bought Over $50K In Brookfield Renewable Stock"
              },
              {
                "id": 140839747,
                "url": "https://finnhub.io/api/news?id=330deea0f937ba4fc68084a259ccf67f7595ac07a1ae24c96525a42b66911ac5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the appointment of Michael McDonnell ...",
                "category": "company",
                "datetime": 1783508400,
                "headline": "Moderna Appoints Michael McDonnell to Board of Directors"
              },
              {
                "id": 140833225,
                "url": "https://finnhub.io/api/news?id=2c21c0d4441f282ca0e4101ecb878317ea4a0bee0ef2c4db4c83a4b62cd67c1a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Ionis completes enrollment in the pivotal pediatric cohort of its phase III REVEAL study, advancing obudanersen toward potential regulatory submissions.",
                "category": "company",
                "datetime": 1783441680,
                "headline": "IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study"
              },
              {
                "id": 140833226,
                "url": "https://finnhub.io/api/news?id=87a299e9a577b4c947d1633e3db6e984a23d7b99ceb98ac5c64a949ffbb1ee28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1783440605,
                "headline": "Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again"
              },
              {
                "id": 140833326,
                "url": "https://finnhub.io/api/news?id=351483ad142a44454c749bbb1cc6bd5f4f8fc0f182938055e907b2088de11551",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $227 to $242.",
                "category": "company",
                "datetime": 1783424303,
                "headline": "RBC Capital Maintains Outperform on Biogen, Raises Price Target to $242"
              },
              {
                "id": 140830203,
                "url": "https://finnhub.io/api/news?id=75014b57a5eaea585df8853c5a378ed4fa238d1cdac808c53590a990dc26c001",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.",
                "category": "company",
                "datetime": 1783417140,
                "headline": "Vertex to acquire Crinetics in $10B foray into endocrine disease drugs"
              },
              {
                "id": 140823559,
                "url": "https://finnhub.io/api/news?id=5a144f07bedba347af467925be73da106be1e89722253a4d07e63d464f1aecad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.",
                "category": "company",
                "datetime": 1783361040,
                "headline": "3 Healthcare ETFs to Own in a Choppy Stock Market"
              },
              {
                "id": 140813366,
                "url": "https://finnhub.io/api/news?id=cb7628a5eb59c83089d360adea3cf8de59497534cd4b7268a622d945dc897161",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that Biogen is scaling back Apellis Pharmaceuticals’ research pipeline and reducing its R&D staff, weeks after completing a $5.6 billion acquisition of the company. Biogen has suspended several legacy research programs, including Phase […]",
                "category": "company",
                "datetime": 1783256354,
                "headline": "Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now"
              },
              {
                "id": 140805970,
                "url": "https://finnhub.io/api/news?id=75ba0c1561046e54f059b8e03c06190d1e9f2b1b0aa1de1a4668ec084aed3fa6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "This could be a key move for future growth.",
                "category": "company",
                "datetime": 1783153320,
                "headline": "Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors."
              },
              {
                "id": 140796522,
                "url": "https://finnhub.io/api/news?id=f96e73508ef4c1871f05c82d55aa25e3236bfd3b6f05e974e87a8457d2b914ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Jay Woods recommended investing in the BioTech ETF and Biogen in particular within the ETF.",
                "category": "company",
                "datetime": 1783036407,
                "headline": "BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers"
              },
              {
                "id": 140789064,
                "url": "https://finnhub.io/api/news?id=ea6d4d8fa618a47292b12f27fc95b4520370ef21c3e722e2dd4f8fc3240d5d4e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.",
                "category": "company",
                "datetime": 1782984744,
                "headline": "1 S&P 500 Stock with Promising Prospects and 2 We Question"
              },
              {
                "id": 140788353,
                "url": "https://finnhub.io/api/news?id=4627183fd380a8cc71c75dc6c5b57184f4f06a2a8a9ba94b186e54a86b7465b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen stock has delivered a strong 57.5% return over the past year, and with the current valuation checks painting a mixed picture rather than a clear bargain or clear overvaluation, investors are weighing how much of the recent Alzheimer’s and immunology news is already reflected in the price. Over the last 12 months, Biogen has returned 57.5%, which puts a spotlight on whether today’s share price still offers an attractive entry point or mainly reflects recent optimism. On the upside,...",
                "category": "company",
                "datetime": 1782976490,
                "headline": "Is Biogen (BIIB) Priced Near Fair Value After Its 57% Run?"
              },
              {
                "id": 140786609,
                "url": "https://finnhub.io/api/news?id=0c6f72604f707ca77cc99f0892a2b36910dedb9a37f0dd8847ea5b813b5f395f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (NasdaqGS:BIIB) plans to present new investigational data from its Alzheimer’s portfolio at AAIC 2026. The company will share detailed Phase 2 CELIA results for diranersen, a tau-targeting therapy. Biogen will also present real-world evidence on subcutaneous lecanemab, including usage patterns and long-term outcomes. For investors tracking Biogen, the AAIC 2026 agenda centers on two core Alzheimer’s assets that are central to the company’s neurodegeneration focus. Diranersen targets...",
                "category": "company",
                "datetime": 1782955123,
                "headline": "Biogen (BIIB) To Share New Alzheimer’s Data At AAIC 2026"
              },
              {
                "id": 140785714,
                "url": "https://finnhub.io/api/news?id=6dc06718c1b7f05fded70240eb3922426e764506b9264330de52d189ad9b31ef",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $164 million on a",
                "category": "company",
                "datetime": 1782923221,
                "headline": "Biogen Expects $164M Q2 2026 And $290M-$320M Q3 2026 IPR&D And Milestone Charges, Impacting Earnings By $0.95 And $1.75–$1.95 Per Share, Respectively"
              },
              {
                "id": 140780654,
                "url": "https://finnhub.io/api/news?id=1bd01f8e61ef51ebcb51cb5b0359bbb686d74196259eb0aebb6161b83b544b3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.",
                "category": "company",
                "datetime": 1782911040,
                "headline": "Amgen or Biogen: Which Biotech Stock Appears Better Poised?"
              },
              {
                "id": 140778902,
                "url": "https://finnhub.io/api/news?id=36ae3ddf6ce459c2e6edb47b311ce5c545f5cb8792df28ebf96d6ed9ee90efb4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "INCHEON, Korea, July 01, 2026--Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). Harrow became responsible for commercialization of BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTIS1 (ranibizumab), and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEA2 (aflibercept), upon full transition of commercialization rights from Biogen back to Samsung Bioepis by the end of 2025.",
                "category": "company",
                "datetime": 1782903600,
                "headline": "Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow"
              },
              {
                "id": 140771665,
                "url": "https://finnhub.io/api/news?id=8733763cfea3199fcae1f691f8e26460883bbd0ad583e34beba2ab050714d917",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BBIB, BGSI and CLCGY have been added to the Zacks Rank #5 (Strong Sell) List on June 30, 2026.",
                "category": "company",
                "datetime": 1782810480,
                "headline": "New Strong Sell Stocks for June 30th"
              },
              {
                "id": 140763996,
                "url": "https://finnhub.io/api/news?id=f241264e1ae813d3d1334adca34d4c30f747d2ac81b88d7e5865f733236d5d8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "LLY, ABBV, BIIB and JNJ hit new 52-week highs as biotech rallies, with company-specific pipeline, approvals and deal activity adding momentum.",
                "category": "company",
                "datetime": 1782745800,
                "headline": "Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs"
              },
              {
                "id": 140761798,
                "url": "https://finnhub.io/api/news?id=99d57115c212434a7b057957cce12094854beb5df466622b622f33c7fe8e0a84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1782734820,
                "headline": "Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?"
              },
              {
                "id": 140760964,
                "url": "https://finnhub.io/api/news?id=b2afb749a7e570b0055be22375ca21f1e31a35a77b363e1dc8b609c955074afc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The pharma company plans to pause or terminate investment in most of Apellis’ legacy research programmes.",
                "category": "company",
                "datetime": 1782733369,
                "headline": "Biogen trims Apellis pipeline and R&D team after $5.6bn takeover"
              },
              {
                "id": 140772579,
                "url": "https://finnhub.io/api/news?id=1d609d0c19b237f1022a11a9c80ade78bdac5c93022f1f88ed7c11c13a77b8bd",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/29/Biogen-World-Headquarters-At-225-Binney-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Analyst raised sales estimates for Spinraza HD due to positive uptake. Biogen makes strides in key priorities. PT increased to $256.",
                "category": "company",
                "datetime": 1782732451,
                "headline": "Biogen: Key Takeaways From Needham’s Meeting With Top Management"
              },
              {
                "id": 140760965,
                "url": "https://finnhub.io/api/news?id=0e12411714cc3b0fa125847d1437c9ba63522338a3c7df8e3c65a803b08fadd2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline results announced in May 2026Lecanemab presentations will highlight emerging data on subcutaneous administration and real-world use, including practical treatment considerations, at-home administration, three-year LEADER data, maintenance dosing and patient experienceAdvances across Biogen’s Alzhei",
                "category": "company",
                "datetime": 1782730740,
                "headline": "Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen"
              },
              {
                "id": 140762076,
                "url": "https://finnhub.io/api/news?id=daf8f48d5b31a92c23d93309085cb937926bf8de723bfa65bffbfd4dff46c9ba",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline results announced",
                "category": "company",
                "datetime": 1782716517,
                "headline": "Biogen To Present New Data Across Alzheimer’s Disease Portfolio At AAIC 2026, Presentations To Include Data From Phase 2 CELIA Study Evaluating Diranersen, And New Analyses From Studies Of LEQEMBI"
              },
              {
                "id": 140762077,
                "url": "https://finnhub.io/api/news?id=ca6fb468047e4b7d80514572e9a244260011d013b1726a33fb48d63e746b0236",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Needham  analyst Ami Fadia   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $255 to $256.",
                "category": "company",
                "datetime": 1782713301,
                "headline": "Needham Maintains Buy on Biogen, Raises Price Target to $256"
              },
              {
                "id": 140741673,
                "url": "https://finnhub.io/api/news?id=43a600fb2ad5438f2f1771c843af456157c82cdfd3013de338867fff4ee08344",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Shares of biotech company Biogen (NASDAQ:BIIB) jumped 5.6% in the afternoon session after investors continued to cheer a string of growth signals, including the $1 billion purchase of RayThera Inc., an FDA Breakthrough Therapy tag for its drug candidate Salanersen, and a recent analyst upgrade.",
                "category": "company",
                "datetime": 1782511705,
                "headline": "Why Biogen (BIIB) Stock Is Up Today"
              },
              {
                "id": 140737991,
                "url": "https://finnhub.io/api/news?id=4f1f92e9bfd556033ca1e9a7a947069be8194bd99d29c4f03bd80a254adeb6e9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Lilly, AbbVie and J&J extend winning streaks.",
                "category": "company",
                "datetime": 1782496164,
                "headline": "Lilly, J&J and AbbVie Hit New Highs"
              },
              {
                "id": 140737291,
                "url": "https://finnhub.io/api/news?id=f967565bde51a202a27c29a0137a0c215d2512f7031b456cec9015d4e7b99a56",
                "image": "https://image.cnbcfm.com/api/v1/image/108222303-1762434766877-gettyimages-2235744008-CANADA_BIOMANUFACTURING.jpeg?v=1782492668&w=1920&h=1080",
                "source": "CNBC",
                "related": "BIIB",
                "summary": "Here are the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1782478763,
                "headline": "Stocks making the biggest moves midday: Moderna, ON Semiconductor, Rocket Lab, Eli Lilly, Sandisk & more"
              },
              {
                "id": 140735458,
                "url": "https://finnhub.io/api/news?id=2e9b468085e3e52dd66253a98be2f9d262c6eac29c83f8fa3ac4282dfe26b889",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen is betting on Leqembi, Skyclarys and Zurzuvae to offset declining legacy drug sales, but replacing lost revenues may take time.",
                "category": "company",
                "datetime": 1782476400,
                "headline": "Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?"
              },
              {
                "id": 140724703,
                "url": "https://finnhub.io/api/news?id=351b3eb19e715a16d21f59dd642061c9d64d6f75ffe01be0818f08d68b71cae8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Axtria Inc., a global leader in AI-first data & analytics solutions and platforms for the life sciences industry, hosted Axtria Ignite 2026 on June 10 and 11 at the Princeton Marriott at Forrestal under the theme \"Industrializing Intelligence: The Agentic Enterprise.\" More than 450 executives from over 100 leading life sciences, MedTech, and biotech organizations gathered to work through the harder question of 2026: what must be true before an enterprise can trust AI to run at machine speed.",
                "category": "company",
                "datetime": 1782389700,
                "headline": "Axtria Ignite 2026: 450+ Life Sciences Leaders Convene With a Contrarian Message -- Fix the Foundation Before You Scale AI"
              },
              {
                "id": 140705774,
                "url": "https://finnhub.io/api/news?id=cd09cb16caa295cab5162b00185ad49078b0906ad5962d5c8eae82875ea48e65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics earnings season.",
                "category": "company",
                "datetime": 1782239086,
                "headline": "Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)"
              },
              {
                "id": 140693916,
                "url": "https://finnhub.io/api/news?id=04e269265cac7427175c0982f245bba6370b6072bbff05dc15f7239bd8257dd9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The cutaneous lupus erythematosus market is expected to witness steady growth over the coming years, driven by increasing disease awareness, improved diagnostic rates, and a growing focus on autoimmune and dermatological disorders. The introduction of novel targeted therapies such as Litifilimab (Biogen), Daxdilimab (Amgen/Horizon Therapeutics), SOTYKTU (Bristol Myers Squibb), IMVT-1402 (Immunovant Sciences), VENT-03 (Ventus Therapeutics), CNTY-101 (Century Therapeutics), and others, and biologi",
                "category": "company",
                "datetime": 1782147600,
                "headline": "Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight"
              },
              {
                "id": 140675161,
                "url": "https://finnhub.io/api/news?id=5444a5704726fc09eac78e6800a2e706e481fee5066427554fafe21bded43966",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Stock Performance Snapshot Biogen (BIIB) has drawn investor attention after a recent move in its share price, with the stock closing at US$196.58. That level sits against a backdrop of mixed short and longer term returns. See our latest analysis for Biogen. Short term momentum for Biogen looks softer, with the 1 day and 7 day share price returns both slightly negative, while the 1 month and year to date share price returns remain positive and the 1 year total shareholder return is...",
                "category": "company",
                "datetime": 1781917830,
                "headline": "Biogen (BIIB) Stock Could Be 10.3% Undervalued on Its Pipeline Narrative"
              },
              {
                "id": 140683227,
                "url": "https://finnhub.io/api/news?id=c4d90fdf5df9ffdb21df7b0ae459abafe14b693d50daf425ed18dce68642d069",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The proposed acquisition will add anti-inflammatory candidates to Biogen, including RayThera’s lead asset.",
                "category": "company",
                "datetime": 1781862498,
                "headline": "Biogen to acquire RayThera for up to $1bn"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 0,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0,
            "source_article_count": 89,
            "discarded_article_count": 70
          },
          "sentimentPoints": 2
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 18.6,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 0.9,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "站上MA50；升放量(近10日3日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 1393496.6666666667,
              "down_days": 5,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 1837040,
              "avg_vol_20": 1619975,
              "avg_vol_30": 1393496.6666666667,
              "range_pct_10": 0.16015342200332916,
              "range_pct_20": 0.1635516256346606,
              "range_pct_30": 0.1635516256346606,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 3,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.3182952237656351,
              "dist_to_20d_high": 0.062488576369925296,
              "down_shrink_days": 2,
              "breakout_level_20d": 219.72,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.9792224405098712
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 4.578571553057354,
              "turnoverUsdM": 236.95030850300003,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.BIIB",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 187.1272,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 9.2,
            "take_profit_price": 218.3137,
            "target_multiplier": 1.6,
            "technical_strength": 1.22,
            "take_profit_percent": 6
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.2,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 9.157143106114708,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.BIIB",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 9.4314,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 4.58
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 39.93
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0229
    },
    "kdj": {
      "d": 42.85,
      "j": 72.39,
      "k": 52.7,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 34.38
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 601800,
      "recentSlope": -248140,
      "previousSlope": 466020
    },
    "rsi": 43.58,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 186.5022,
      "position": "SAR喺價下",
      "distancePct": 9.46,
      "previousTrend": "上升"
    },
    "ma50": 198.8126,
    "macd": {
      "macd": 1.1639267907896453,
      "trend": "中性偏多",
      "signal": 1.844093963136028,
      "histogram": -0.6801671723463827
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 6,
      "value": 203.4235,
      "position": "連續1-2日>VWAP",
      "consecutiveAbove": 2
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.71,
      "score": 2,
      "avgVolume": 1627040,
      "currentVolume": 1150300
    },
    "derived": {
      "ma20": 204.766,
      "ma50": 198.8126,
      "prevClose": 208.92,
      "avgVolume10": 1836560,
      "avgVolume20": 1627040,
      "changePercent": -1.4,
      "avgVolumeForScore": 1627040
    },
    "ma_cross": {
      "ma20": 204.766,
      "ma50": 198.8126,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 204.4,
      "prevMa50": 198.4754,
      "spreadPct": 2.99,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 189.994,
      "upper": 219.538,
      "position": "上半部"
    },
    "rsi_short": 57.52,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.71
    }
  }
}

{
  "close": 205.99,
  "volume": 1150300,
  "changePercent": -1.4
}